Interim phase 3 trial results found sotrovimab reduced the risk of hospitalisation or death by 85% compared to placebo
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.